Pune, India, Oct. 25, 2023 (GLOBE NEWSWIRE) -- According to our new research study on “Rapid Influenza Diagnostic Tests Market covers analysis By Test Type (Influenza A Tests, Influenza B Test, and Influenza A+B Test); Sample Type (Nasal Swab, Throat Swab, Nasopharyngeal Swab, and Others); Technology [Immunochromatographic Assays, Immunofluorescence Assays, and Nucleic Acid Amplification Test (NAAT)]; End User (Hospitals and Clinics, Diagnostic Centers, Nursing Homes, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)”; the global rapid influenza diagnostic tests market growth is propelled by the increasing prevalence of influenza and the popularity of rapid tests.
Download Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00017827
Global Rapid Influenza Diagnostic Tests Market Analysis: Competitive Landscape and Key Developments
Thermo Fisher Scientific Inc., Hologic, Abbott Laboratories, Siemens Helathineers AG, Quidel Corporation, Danaher Corporation, Meridian Bioscience, F. Hoffmann-La Roche, Becton Dickinson and company, and Luminex Corporation among others are a few of the key companies operating in the rapid influenza diagnostic tests market. The market leaders focus on expansion and diversification, new product launches, and acquisition strategies, which enable them to access prevailing business prospects.
In May 2023, MaximBio is granted a contract from NIH to develop a new rapid test platform. The company will develop a combo test for Covid-19 and Influenza A/B combo test based on lateral-flow assay (LFA) technology.
In December 2020, DiaSys launched the cartridge-based rapid tests for the diagnosis of Influenza A&B, COVID-19 antigens and IgM and IgG antibodies as well as SGTi-flex COVID-19 & Flu A/B Ag DUO. These rapid tests are easy and reliable and provide accurate results within a short period.
Recent Developments in Global Rapid Influenza Diagnostic Tests Market
The healthcare is a developing industry, especially in developing and underdeveloped economies and has experienced an increase in healthcare facilities and infrastructure in recent years. There has been an increase in healthcare expenditure in the countries for the further development of healthcare services. Additionally, the market players operating the healthcare industry are focused on research and development activities, which has increased the research and development activities leading to new product launches, innovation, collaboration, and product approval in the rapid influenza diagnostic test market. Some of the recent developments include:
In June 2023, Kaneka Corporation received authorization for the manufacture and sale of “KANEKA Immunochromatography Flu A/B & SARS-CoV-2 Ag”, which can test for COVID-19 (SARS-CoV-2) and influenza virus antigens in a single sample collection.
In March 2023, Lucira Health, Inc. launched Lucira COVID-19 & Flu Home Test in the US and the combination test's inclusion in the Australian Register of Therapeutic Goods (ARTG) for use by healthcare professionals in a point-of-care environment. The COVID-19 & Flu Home Test is the first and only over-the-counter (OTC) combination COVID-19 & F8lu test approved by the U.S. Food and Drug Administration (FDA) and to be granted emergency use authorization (EUA) at home and other non-laboratory sites.
In January 2023, 2San launched a dual kit for SARS-CoV-2 & Influenza A+B. With the ongoing demand set upon the NHS post pandemic, the over-the-counter kit has been launched to help alleviate pressures on healthcare institutions.
In September 2022, Siemens Healthineers launched its new CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test.
In November 2020, SEKISUI Diagnostics announces received CE Marking (Conformité Européenne) for the OSOM Ultra Plus Flu A&B Test and has begun marketing in Europe.
Therefore, increase in product launches, product approvals, and other strategic collaborations are expected to create ample opportunities for the rapid influenza diagnostic tests market, driving the market growth.
Order a Copy of this Report at https://www.theinsightpartners.com/buy/TIPRE00017827
Global Rapid Influenza Diagnostic Tests Market: Segmental Overview
Based on test type, the global rapid influenza diagnostic tests market is segmented into influenza A test, influenza B test, and influenza A+B test. In 2022, the influenza A+B test segment held the largest market share and is expected to grow fastest during the coming years. Based on sample type, the rapid influenza diagnostic tests market is segmented into nasal swabs, throat swabs, nasopharyngeal swabs, and others. In 2022, the nasopharyngeal swab segment held the largest share of the market and is expected to grow at the fastest rate during the coming years. The rapid influenza diagnostic tests market is segmented based on technology into immunochromatographic assays, immunofluorescence assays, and nucleic acid amplification test (NAAT). In 2022, the immunochromatographic assays segment held the largest market share and expected to grow fastest in the coming years. The rapid influenza diagnostic tests market is segmented into hospitals and clinics, diagnostic centers, nursing homes, and others based on end user. In 2022, the hospitals and clinics segment held the largest share of the market. In addition, the diagnostic centers segment is also expected to grow at the fastest rate during the coming years.
Go through further research published by The Insight Partners:
Influenza Diagnostics Market - Global Analysis and Forecast to 2030
General Influenza Diagnostics Market - Global Analysis and Forecast to 2030
Molecular Influenza Test Market - Global Analysis and Forecast to 2030
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
